Țintirea bolilor rare
AOP Health este pionier în Europa în dezvoltarea, producerea și comercializarea de tratamente pentru persoanele cu boli rare, cunoscute și ca boli orfane.
As a privately owned company AOP Health is devoted to long-term commitment, high quality, and continuity. For a small number of very special diseases the company is the sole supplier of some key therapeutic agents throughout the world.
"Obiectivul nostru este de a ne extinde portofoliul cu medicamente eficiente, aducând tratamente inovatoare pentru pacienții cu boli rare. Prin urmare, obiectivul nostru în 2019 este de a obține includerea unor noi molecule în lista de medicamente compensate, care să ofere pacienților români terapii de înaltă calitate, la care toți cetățenii UE au dreptul.
Lucrăm împreună ca o echipă dinamică, flexibilă și pasionată, cu motivație și dedicare puternică, pentru a atinge acest obiectiv!”"
Founding
Why did you found AOP Health?
“When founding AOP Health in 1996 – as AOP Orphan – my aim was to make targeted treatment available to the maximum number of patients with rare diseases. I realized that these patients are frequently left alone in their suffering. As an entrepreneur the complex environment of rare diseases was a great challenge, but also an opportunity to be successful in this niche.”
What role did AOP Health’s sense of entrepreneurial responsibility play in the founding of the company?
“Entrepreneurial responsibility is no additionally imposed obligation for AOP Health, but the attitude that played an indispensable role at the very time the company was founded. AOP Health’s objective to provide effective help for persons with rare diseases originated from this sense of responsibility and has made the company what it is today.“
AOP Orphan – now AOP Health – was founded in 1996 by Dr. Rudolf Widmann with the aim of developing and providing therapy options for patients with rare diseases, and then introducing the therapy options first in Austria, the European core countries of AOP Health, and finally in the international market.
“I worked for several years in large international pharmaceutical companies and observed that there were some therapy options for rare diseases, but they did not reach the large majority of the patients.”
DATE ȘI STATISTICI
Compania AOP Health este dedicată pe deplin dezvoltării farmaceutice și clinice, precum și comercializării medicamentelor, de peste 20 de ani.
Motivația noastră, în cadrul companiei AOP Health, este de a ajuta pacienții care suferă de boli rare. Realizăm acest lucru prin colaborarea cu părțile interesate din sistemul de sănătate din România. Parteneriatele din cadrul industriei farmaceutice și de sănătate sunt esențiale pentru găsirea și furnizarea de soluții pentru pacienți, în special în tratamentul bolilor rare.
România ocupă o poziție specială printre țările în care compania AOP Health este reprezentată. Compania a început să se dezvolte pe această piață în 2008. AOP Health Romania este o echipă de aproximativ cinci angajați în departamentul Marketing și Vânzări și în departamentul Medical, pentru toate cele trei domenii de tratament.
Vision & Mission
Milestones
History of more than 20 years means many significant milestones — in research, social, business spheres and regulatory affairs — that were and are important for AOP Health.
Foundation of AOP Health in Vienna
The Orphan Regulation EC no 141/2000
1st Approval of Anagrelide in Europe
European Union Expansion
Prostacyclin Analogues Approval
JAK2 Discovery
Renaissance of Interferon (IFNα)
UDCA Designation
Tetrabenazine Approval in Central Europe
Nabilone Approval in Austria
Start of the PROUD PV Study
Beta-blocker for severe sepsis
Pitolisant approval
Landiolol approval
Treprostinil and PAH
BESREMi® Approval
Corporate culture
Since its very start AOP Health has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders.
AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.
The future
Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.
Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.
Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.
Echipa AOP Health acoperă toate aspectele esențiale ale dezvoltării produsului, începând cu cercetarea și toxicologia preclinică și continuând cu dezvoltarea farmaceutică și clinică, inclusiv aspectele de reglementare, managementul calității și farmacovigilență.
Parteneriatele au o importanță majoră pentru AOP Health. Acestea permit dezvoltarea în continuare a portofoliului AOP Health pentru boli rare și permit abordarea pacienților dincolo de piețele de bază ale companiei în Europa.